Abstract 48P
Background
PD-L1 negative aNSCLC is less responsive to immunotherapy. The 9LA regimen combines ipi/nivo with two cycles of platinum-doublet chemotherapy and demonstrated superior efficacy compared to chemotherapy alone for aNSCLC, also in the PD-L1 negative subpopulation. The RW-9LA study aims to collect real-world data on efficacy and toxicity of the 9LA regimen in PD-L1 negative, advanced NSCLC.
Methods
This is a retrospective, single center, study conducted at UZ Brussel, Brussels, Belgium. All pts diagnosed with PD-L1 negative, aNSCLC treated with the 9LA regimen between February 2022 and October 2024 were included. Primary endpoints were objective response rate (ORR) and progression free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs).
Results
40 pts were included with median age 70 years and 25% demonstrating a performance status ≥2. All patients were smokers or former smokers. 72.5% demonstrated non-squamous histology. ORR was 40% with three pts demonstrating a metabolic complete remission. Median PFS was 5.5 months (95%CI 2.9–8.1) while median OS was 22.9 months (95%CI 15.2–30.6). AEs of all grades were reported in 95% with 42.5% grade 3/4. The most frequent reported AEs were fatigue (70%), anorexia (55%) and pruritus (45%). Suspected immune-related (ir) AEs were observed in 65% of patients with 22.5% grade 3/4.
Conclusions
Our real-world analysis confirms the activity of the 9LA regimen in PD-L1 negative, aNSCLC. No new safety signals were observed but ir AEs are frequent and should be monitored closely.
Legal entity responsible for the study
Department Medical Oncology, UZ Brussel.
Funding
Has not received any funding.
Disclosure
L. Decoster: Financial Interests, Institutional, Invited Speaker: BMS, MSD, AstraZeneca, Johnson & Johnson, Roche; Financial Interests, Institutional, Advisory Board: BMS, Johnson & Johnson, MSD, Roche, AstraZeneca. K. Vekens: Financial Interests, Institutional, Invited Speaker: Johnson & Johnson. All other authors have declared no conflicts of interest.